Many patients and physicians assume that the safety and effectiveness of newly approved therapeutic agents is well understood; however, the strength of the clinical trial evidence supporting approval decisions by the US Food and Drug Administration (FDA) has not been evaluated.
The clinical research findings available at the time of a drug's approval have important implications: if made public, these findings represent the only source of information available to patients and their physicians as they decide whether to use a newly approved drug. However, flexible approval standards may lead to some therapeutic agents being approved by the FDA on the basis of numerous rigorously designed clinical trials and others on the basis of fewer or less robust studies, leading to differing levels of certainty about the risks and benefits of newly approved drugs. Accordingly, we sought to systematically examine this issue, evaluating the strength of the clinical trial evidence supporting FDA approval decisions for novel therapeutic agents-pharmacologics and biologicsbetween 2005 and 2012 by characterizing key features of pivotal efficacy trials, such as trial size, design, duration, and end points.
Methods

Data Sources
Drugs@FDA is a publicly accessible database available through the FDA's website that lists regulatory actions, such as approvals and drug labeling changes, for all currently approved prescription therapeutic agents. Records for each approved agent are hyperlinked to FDA medical reviews, which are lengthy documents that outline the clinical evidence used to establish the efficacy and safety of the novel agent prior to approval. The Drugs@FDA database was downloaded on January 11, 2012, and on May 1, 2013. Medical reviews were accessed several times between January 2012 and June 2013.
Study Sample
We constructed a sample of novel therapeutic agents (ie, new molecular entities or novel biologic drugs) first approved by the FDA between January 1, 2005, and December 31, 2012, excluding generic drugs, reformulations, and combination therapies of nonnovel therapeutic agents ( Figure) . We also excluded nontherapeutic agents, such as diagnostic and contrast agents (eAppendix 1 in Supplement), and removed any duplicate records.
Therapeutic Agent and Indication Characteristics
Using information provided within the Drugs@FDA database, we categorized each novel therapeutic agent by year of approval and as a pharmacologic entity (ie, small molecule) or biologic. 13 Additionally, agents were classified by orphan status, a designation made by the FDA that affords extended market exclusivity for drugs that treat rare diseases (the Drugs@FDA database only indicates orphan status for biologics approved after 2010). Using FDA approval letters, which are also hyperlinked in the Drugs@FDA database, we identified therapeutic agents approved through the accelerated approval pathway and the indication for which all novel therapeutic agents were initially approved for use. Subsequently, indications were categorized by expected length of treatment: acute, intermediate, or chronic. The expected length of use was less than 1 month for acute treatments, between 1 month and 2 years for intermediate treatments, and greater than 2 years for chronic treatments (eAppendix 2 in Supplement). Additionally, we used the World Health Organization's Anatomic Therapeutic Classification system, contextualized for clinical relevance, to categorize each indication into 1 of 8 therapeutic areas. 14 Last, 2 investigators (N.S.D., J.S.R.) determined the total number of patients exposed to the novel therapeutic agent during clinical development, ie, the total safety population (eAppendix 3 in Supplement). 
Identification of Pivotal Efficacy Trials
For each novel therapeutic agent, 1 investigator (J.A.A.) identified the pivotal efficacy trials used as the basis for approval. Generally, these trials are labeled in FDA medical reviews as "pivotal," and their design and findings are discussed in detail. For approvals in which no trial was explicitly labeled "pivotal" in the FDA medical review, we identified trials described as essential to approval or those prioritized within the review using criteria such as substantial discussion of study design (ie, inclusion and exclusion criteria, thorough description of study protocol) and independent analysis of results (ie, not pooled with other studies). Additionally, any efficacy trial reviewed as part of a resubmitted application was considered pivotal to approval.
Two investigators (N.S.D., J.S.R.) subsequently validated identification of all pivotal efficacy trials through independent review, resolving conflicts by consensus.
Pivotal Efficacy Trial Features
Each pivotal trial was categorized according to its use of randomization and blinding based on the FDA reviewer's description of the trial. In addition, we also recorded the type of comparator, primary trial end point(s), the number of treated patients (overall and intervention group), trial duration, and completion rate (eAppendix 3 in Supplement). Completion rate was calculated by dividing the number of patients completing the trial by the number of treated patients (overall and intervention group 
Statistical Analysis
Using descriptive statistics, we characterized the novel therapeutic agents included in our sample and the indications for which they were initially approved for use. Next, we used descriptive statistics to characterize features across the overall sample of pivotal efficacy trials as well as the features of these trials aggregated at the indication level, ie, the summary of all pivotal efficacy trials used to support the approval of each indication. We then used χ 2 , Wilcoxon, and Kruskal-Wallis tests as appropriate to examine differences among novel therapeutic agent and indication characteristics, including therapeutic area, expected length of therapy, agent type, orphan status, and accelerated approval, all of which were preplanned prior to data collection. Analyses were performed using Microsoft Excel 2010 and JMP version 7.0.1 (SAS Institute Inc). All statistical tests were 2-tailed and used a type I error rate of .01 to account for multiple comparisons across 5 therapeutic agent and indication characteristics.
Results
Between 2005 and 2012, the FDA approved 188 novel therapeutic agents: 154 (81.9%) were pharmacologics and 34 (18.1%) were biologics. The FDA had granted orphan status to 31 (16.5%), and 22 (11.7%) were approved through the accelerated approval pathway ( Table 1) . These 188 novel 
Pivotal Efficacy Trial Features
Pivotal efficacy trials were identified for 201 of 206 indications ( Figure) ; 4 novel therapeutic agents were approved (1 for 2 indications) without a pivotal efficacy trial. A total of 448 pivotal trials were identified: 283 (63.2%) were explicitly labeled "pivotal," and 165 (36.8%) were inferred as pivotal based on the criteria described previously. 
Aggregated Trial Features Supporting Approved Indications by Therapeutic Agent and Indication Characteristics
The features of the aggregated pivotal efficacy trials supporting approved indications differed by therapeutic agent and indication characteristics. Most therapeutic agents approved for cancer indications were approved on the basis of a single trial, whereas the approval of therapeutic agents for cardiovascular disease, diabetes mellitus, or hyperlipidemia and for psychiatric indications often relied on at least 3 trials (Tables 4 and 5 ). Median numbers of overall and intervention group patients were larger among aggregated trials supporting indications within these therapeutic areas.
There was no difference in the proportion of indications approved through the accelerated approval pathway on the basis of multiple trials when compared with nonaccelerated approval 
Discussion
Our characterization of pivotal efficacy trials-trials that serve as the basis of FDA approval-for all novel therapeutic agents approved between 2005 and 2012 demonstrates that the quality of clinical trial evidence used by the FDA to make approval decisions varied widely across indications. Although the vast majority of indications were supported by at least 1 randomized, double-blinded trial, there was wide variation in trials' choice of comparators and end points, duration, size, and completion rate. In addition, just more than one-third of indications were approved on the basis of a single pivotal efficacy trial.
The variation in the quality of clinical trial evidence used by the FDA to assess the efficacy of novel therapeutic agents highlights the agency's flexible standards for approval. Such regulatory flexibility allows for a customized approach to approval, including the ability to rapidly approve potentially effective therapies for life-threatening diseases, such as certain cancers, or those diseases for which there is no existing effective treatment, such as orphan diseases. These approv- 20 and has cited its willingness to rapidly approve new drugs in recent year-end reviews of drug approvals. 21, 22 Substantial variation has been described among pivotal efficacy trials supporting the approval of cancer drugs, 23 and this flexibility may well be warranted given the limited number of effective therapies and the poor prognosis associated with cancer. Understanding the strength of clinical trial evidence of newly approved therapeutic agents has important implications for patients and physicians. When medications become available on the market, decisions must be made about their use, likely informed by how well safety and effectiveness are understood. Comparative effectiveness information, which is but leaving uncertainty about the benefits and safety of these medications when compared with other available therapeutic agents. Similarly, although patient-important clinical outcomes and scales were used in many pivotal trials, trials using surrogate end points as their primary outcome formed the exclusive basis of approval for nearly half of the approved indications in our study. This reliance on surrogate outcomes leaves patients and physicians to extrapolate clinical benefits from trials, again raising questions about the certainty of the medications' benefits in practice. 25 Last, we found that the majority of trials evaluating therapeutic agents indicated for chronic treatment lasted less than 1 year, raising questions about the certainty of these medications' long-term efficacy and safety. Because comprehensive safety evaluations are difficult to undertake as part of randomized controlled trials, particularly smaller trials, these findings clarify the importance of adopting a "life-cycle" approach, both for drug safety and for improved understanding of drug effectiveness. In 2006, the Institute of Medicine Report on the Future of Drug Safety recommended that the FDA monitor and evaluate the benefits and risks of drug therapies not only prior to their approval but throughout their entire market life.
26 This so-called life-cycle approach suggests that new information on the benefits and safety of therapeutic agents should be continually collected. It also requires adequate and robust postmarket surveillance systems that allow reassessments of drug efficacy and safety after market introduction. However, communicating this updated information to patients and physicians is critical. A recent Institute of Medicine committee report similarly recommended that the FDA implement a benefit and risk assessment and management plan that would summarize the FDA's evaluation of a drug's benefitrisk profile in a single document and that would be continu- b For therapeutic agents approved for multiple indications, the safety population is the pooled number of patients exposed to the drug.
Alternatively, or as part of this effort, the FDA could provide a summative statement, or even a grade, for each approval to signal the quality of clinical trial evidence used to determine safety and efficacy, allowing therapeutic agents approved on the basis of more robust evidence to be distinguished from those approved on the basis of less robust evidence. Just as the FDA has publicly declared its intention to encourage investigators to use innovative trial designs that are as effective as standard designs but less burdensome and time-consuming and to identify qualifying biomarkers that accurately predict outcomes to make clinical trials more efficient, 29 it also must ensure that patients and physicians understand how to interpret the results of these trials and the likelihood of experiencing benefit or harm when deciding to use these newly approved agents. Our study has several limitations. Although pivotal efficacy trials represent the primary source of information about novel therapeutic efficacy at approval, other trials that provide supplementary efficacy data are discussed transiently in FDA medical reviews but were not systematically assessed. Although the FDA is more likely to first approve novel therapeutic agents for use, 30 the agency also may rely on information from use of the drugs in other countries when evaluating these agents for approval, and we did not assess this information. Additionally, efficacy represents just one component of FDA review, which also covers safety, pharmacology, chemistry, and manufacturing. Last, our study was limited to the approval of new molecular entities and novel biologics; however, because reformulated and generic drugs can be approved on the basis of bioequivalence studies, it is likely that our study captured the majority of pivotal efficacy trials used for evaluations of novel therapeutic agents. Moreover, our findings are consistent with a prior study of high-risk cardiovascular devices, which found many to be approved on the basis of trials that lack adequate strength and may be prone to bias. 31 
Conclusions
The quality of clinical trial evidence used by the FDA as the basis of approvals of novel therapeutic agents between 2005 and 2012 varied widely across indications. This variation has important implications for patients and physicians as they make decisions about the use of newly approved therapeutic agents and has the potential to inform current FDA regulatory approval standards and postmarket surveillance initiatives.
